Overview

Cutivate Lotion HPA Axis Pediatric Study

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.

Phase:

Phase 4

Details

Lead Sponsor:

Fougera Pharmaceuticals Inc.

Treatments:

Fluticasone
Xhance